Dynamic Changes in NPAR and the CALLY Score for Predicting Pathological Complete Response in Breast Cancer: A Simple Combined Clinical Score
Authors:
- Bünyamin GüneyBGBünyamin Güney
- Özgür HanÖHÖzgür Han
- Semih SağırSSSemih Sağır
- Başak Çakır GüneyBGBaşak Çakır Güney
- Didar ŞenocakDŞDidar Şenocak
- Rıza Umar GürsuRGRıza Umar Gürsu
- 22 July 2026
- journal article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 26 (9) , 114-120
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Breast cancerThe Lancet, 2021
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast CancerNew England Journal of Medicine, 2019
- Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast CancersJournal of Clinical Oncology, 2015
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer SubtypesJournal of Clinical Oncology, 2012
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working GroupJNCI: Journal of the National Cancer Institute, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Immunity, Inflammation, and CancerCell, 2010
- Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant ChemotherapyJournal of Clinical Oncology, 2007